Pfizer's Exubera Inhaled Insulin To Be Reviewed By Endocrine Committee Sept. 8
This article was originally published in The Pink Sheet Daily
Executive Summary
Inhalation powder will be evaluated for diabetes mellitus in adults by FDA's Endocrinologic & Metabolic Drugs Advisory Committee. Developed in conjunction with Sanofi-Aventis, Exubera would be first inhaled insulin product.
You may also be interested in...
Exubera Efficacy In Type 1 Diabetes "Intensive" Control Questioned By FDA
Pfizer/Sanofi trial shows only 23% of Type 1 diabetes patients receiving inhaled insulin achieved standard of care for glycemic control, FDA tells advisory committee in briefing materials for Sept. 8 meeting.
Exubera Efficacy In Type 1 Diabetes "Intensive" Control Questioned By FDA
Pfizer/Sanofi trial shows only 23% of Type 1 diabetes patients receiving inhaled insulin achieved standard of care for glycemic control, FDA tells advisory committee in briefing materials for Sept. 8 meeting.
Bristol's Abatacept, Muraglitazar To Go Before Advisory Committees In September
Orencia (abatacept) for moderately to severely active rheumatoid arthritis will be reviewed by FDA's Arthritis Drugs Advisory Commmittee. Pargluva (muraglitazar) will be considered by FDA's Endocrinologic & Metabolic Drugs Advisory Committee for type II diabetes mellitus.